Non-Hodgkin lymphoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Non-Hodgkin lymphoma}}
{{Non-Hodgkin lymphoma}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{Preeti}}
==Overview==
==Overview==


==Epidemiology and Demographics==
==Epidemiology and Demographics==
*Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy in the world.<ref name="pmid9739436">{{cite journal| author=Anderson JR, Armitage JO, Weisenburger DD| title=Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 7 | pages= 717-20 | pmid=9739436 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9739436  }} </ref>
*NHL ranks as the 7th most common cancer among males and the 6th most common cancer among females.<ref name="pmid9739436">{{cite journal| author=Anderson JR, Armitage JO, Weisenburger DD| title=Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 7 | pages= 717-20 | pmid=9739436 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9739436  }} </ref>
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The incidence/prevalence of Non Hodgkin Lymphoma is approximately 13.2 per 100,000 individuals worldwide.<ref name="pmid9739436">{{cite journal| author=Anderson JR, Armitage JO, Weisenburger DD| title=Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 7 | pages= 717-20 | pmid=9739436 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9739436  }} </ref>
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
 
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*Non Hodgkin Lymphoma is the 6th most common cause of cancer related death in the world.<ref name="pmid9739436">{{cite journal| author=Anderson JR, Armitage JO, Weisenburger DD| title=Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 7 | pages= 717-20 | pmid=9739436 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9739436  }} </ref>
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Patients of all age groups may develop Non Hodgkin Lymphoma.<ref name="pmid18796628">{{cite journal| author=Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S et al.| title=Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. | journal=Blood | year= 2008 | volume= 112 | issue= 13 | pages= 5150-60 | pmid=18796628 | doi=10.1182/blood-2008-01-133587 | pmc=2597610 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18796628  }} </ref>
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*B and T cell lymphoblastic lymphoma/leukemia occurs most frequently in children and adults greater than 65 years of age.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.  
*Burkitt Lymphoma affects individuals between 20–64 years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*Primary mediastinal large B-cell lymphoma has a median age of 35.
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*Non Hodgkin Lymphoma usually affects individuals of the Caucasian race.<ref name="pmid15480663">{{cite journal| author=Müller AM, Ihorst G, Mertelsmann R, Engelhardt M| title=Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. | journal=Ann Hematol | year= 2005 | volume= 84 | issue= 1 | pages= 1-12 | pmid=15480663 | doi=10.1007/s00277-004-0939-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15480663  }} </ref>
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
* In the US, the relative risk (RR) of HIV-associated NHL in African-American is half that of Caucasians (RR 22.3, 95% CI, 17.1–29 vs. RR 46.2, 95% CI, 38.8–55) mainly due to ethnic variations in immune system regulatory genes.<ref name="pmid21172877">{{cite journal| author=Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O| title=Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States. | journal=J Clin Oncol | year= 2011 | volume= 29 | issue= 4 | pages= 378-85 | pmid=21172877 | doi=10.1200/JCO.2010.30.1515 | pmc=3058284 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21172877  }} </ref>
 
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Men are more commonly affected by Non Hodgkin Lymphoma than women. The Male to female ratio is approximately 1.5:1 to 3:1.<ref name="pmid16150940">{{cite journal| author=Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS| title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. | journal=Blood | year= 2006 | volume= 107 | issue= 1 | pages= 265-76 | pmid=16150940 | doi=10.1182/blood-2005-06-2508 | pmc=1895348 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16150940  }} </ref><ref name="pmid21261679">{{cite journal| author=Roman E, Smith AG| title=Epidemiology of lymphomas. | journal=Histopathology | year= 2011 | volume= 58 | issue= 1 | pages= 4-14 | pmid=21261679 | doi=10.1111/j.1365-2559.2010.03696.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21261679  }} </ref><ref name="pmid20853323">{{cite journal| author=Ansell P, Simpson J, Lightfoot T, Smith A, Kane E, Howell D et al.| title=Non-Hodgkin lymphoma and autoimmunity: does gender matter? | journal=Int J Cancer | year= 2011 | volume= 129 | issue= 2 | pages= 460-6 | pmid=20853323 | doi=10.1002/ijc.25680 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20853323  }} </ref>
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


===Region===
===Region===
*The majority of [disease name] cases are reported in [geographical region].
*The majority of Non Hodgkin Lymphoma cases are reported in North America, Africa and East Asia.<ref>Swerdlow S, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. 4. Lyon; 2008. p. 439.</ref>
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==

Revision as of 00:50, 20 January 2019

Non-Hodgkin lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Hodgkin's Lymphoma

Differentiating Non-Hodgkin Lymphoma from Other Diseases
Differentiating Types of Non-Hodgkin's Lymphoma

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non-Hodgkin lymphoma epidemiology and demographics On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-Hodgkin lymphoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-Hodgkin lymphoma epidemiology and demographics

CDC on Non-Hodgkin lymphoma epidemiology and demographics

Non-Hodgkin lymphoma epidemiology and demographics in the news

Blogs on Non-Hodgkin lymphoma epidemiology and demographics

Directions to Hospitals Treating Non-Hodgkin lymphoma

Risk calculators and risk factors for Non-Hodgkin lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Overview

Epidemiology and Demographics

  • Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy in the world.[1]
  • NHL ranks as the 7th most common cancer among males and the 6th most common cancer among females.[1]

Incidence

  • The incidence/prevalence of Non Hodgkin Lymphoma is approximately 13.2 per 100,000 individuals worldwide.[1]

Case-fatality rate/Mortality rate

  • Non Hodgkin Lymphoma is the 6th most common cause of cancer related death in the world.[1]

Age

  • Patients of all age groups may develop Non Hodgkin Lymphoma.[2]
  • B and T cell lymphoblastic lymphoma/leukemia occurs most frequently in children and adults greater than 65 years of age.
  • Burkitt Lymphoma affects individuals between 20–64 years of age.
  • Primary mediastinal large B-cell lymphoma has a median age of 35.

Race

  • Non Hodgkin Lymphoma usually affects individuals of the Caucasian race.[3]
  • In the US, the relative risk (RR) of HIV-associated NHL in African-American is half that of Caucasians (RR 22.3, 95% CI, 17.1–29 vs. RR 46.2, 95% CI, 38.8–55) mainly due to ethnic variations in immune system regulatory genes.[4]

Gender

  • Men are more commonly affected by Non Hodgkin Lymphoma than women. The Male to female ratio is approximately 1.5:1 to 3:1.[5][6][7]

Region

  • The majority of Non Hodgkin Lymphoma cases are reported in North America, Africa and East Asia.[8]

References

  1. ↑ 1.0 1.1 1.2 1.3 Anderson JR, Armitage JO, Weisenburger DD (1998). "Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project". Ann Oncol. 9 (7): 717–20. PMID 9739436.
  2. ↑ Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S; et al. (2008). "Etiologic heterogeneity among non-Hodgkin lymphoma subtypes". Blood. 112 (13): 5150–60. doi:10.1182/blood-2008-01-133587. PMC 2597610. PMID 18796628.
  3. ↑ Müller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005). "Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology". Ann Hematol. 84 (1): 1–12. doi:10.1007/s00277-004-0939-7. PMID 15480663.
  4. ↑ Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O (2011). "Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States". J Clin Oncol. 29 (4): 378–85. doi:10.1200/JCO.2010.30.1515. PMC 3058284. PMID 21172877.
  5. ↑ Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–76. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
  6. ↑ Roman E, Smith AG (2011). "Epidemiology of lymphomas". Histopathology. 58 (1): 4–14. doi:10.1111/j.1365-2559.2010.03696.x. PMID 21261679.
  7. ↑ Ansell P, Simpson J, Lightfoot T, Smith A, Kane E, Howell D; et al. (2011). "Non-Hodgkin lymphoma and autoimmunity: does gender matter?". Int J Cancer. 129 (2): 460–6. doi:10.1002/ijc.25680. PMID 20853323.
  8. ↑ Swerdlow S, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. 4. Lyon; 2008. p. 439.
Retrieved from "https://www.wikidoc.org/index.php?title=Non-Hodgkin_lymphoma_epidemiology_and_demographics&oldid=1537752"